3G3-20463-80412
3 vaccinations
5 coded responses
24 check-ins
4 free-text entries
1 call case
- Sex
- Female
- Age at first dose
- 41-45
- ZIP prefix
- 913 / CA
- Registered
- 2021-04-18
- Relationship
- Self
- Race
- White
- Ethnicity
- Hispanic or Latino
Timeline
-
2021-04-16
Dose 1 — Pfizer-BioNTech
-
2021-04-18
Registered in v-safe
-
2021-04-19
Survey response — days 1–6 daily, dose 1MedDRA: Diarrhoea, Nausea — Feeling: Good · Fatigue or tiredness · Be unable to do your normal daily activitiesFree text: Had diarrhea and nausea the first two days but today the symptoms have dissipatedMedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
- 2021-04-20
- 2021-04-21
- 2021-04-22
-
2021-04-23
Survey response — day 7, dose 1MedDRA: Eye pain — Feeling: GoodFree text: Eye painMedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
- 2021-04-30
-
2021-05-07
Dose 2 — Pfizer-BioNTech
- 2021-05-07
-
2021-05-08
Health check-in — days 1–6 daily, dose 2Feeling: Fair · Site: Pain · Fever · Chills, Joint pains, Muscle or body aches, Fatigue or tiredness · Be unable to do your normal daily activitiesAdult check-in
-
2021-05-09
Survey response — days 1–6 daily, dose 2MedDRA: Eye pain — Feeling: Fair · Site: Pain · Fever · Chills, Headache, Joint pains, Muscle or body aches, Fatigue or tiredness · Be unable to do your normal daily activitiesFree text: Eye painMedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
-
2021-05-10
Survey response — days 1–6 daily, dose 2MedDRA: Dizziness — Feeling: Fair · Fatigue or tiredness · Be unable to work, Be unable to do your normal daily activitiesFree text: Felt faintMedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
- 2021-05-11
- 2021-05-12
- 2021-05-13
- 2021-05-14
- 2021-05-21
- 2021-05-28
- 2021-06-04
- 2021-06-11
- 2021-06-18
- 2021-08-06
- 2021-11-05
- 2022-05-07
-
2022-07-15
Dose 3 — Pfizer-BioNTech
- 2022-10-15
-
2023-01-13
Survey response — 6 months, dose 3MedDRA: Anosmia, Chills, Cough, Headache, Pyrexia — Feeling: Good · Be unable to work or attend school, Be unable to do your normal daily activities, Get care from a doctor or other healthcare professional · Telehealth, virtual health, or email health consultationMedDRA releases: 2024-11
-
2023-01-13
Report sent to call center — 6 months, dose 3Be unable to work or attend school · Be unable to do your normal daily activities · Get care from a doctor or other healthcare prTelehealth, virtual health, or email health consultation · 1 call case(s)
- 2023-01-16
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-04-16 | Pfizer-BioNTech | |
| 2 | 2021-05-07 | Pfizer-BioNTech | |
| 3 | 2022-07-15 | Pfizer-BioNTech | No |
Call center
| Reported | Outcome | VAERS-related outcome |
|---|---|---|
| 2023-01-13 | Unsuccessful |
Free text
Release 7 — days 1–6 daily, dose 1
Systemic reaction (other): Had diarrhea and nausea the first two days but today the symptoms have dissipated
Release 7 — day 7, dose 1
Systemic reaction (other): Eye pain
Release 8 — days 1–6 daily, dose 2
Systemic reaction (other): Eye pain
Systemic reaction (other): Felt faint
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Anosmia | · | · | ✓ |
| SD | Chills | · | · | ✓ |
| SD | Cough | · | · | ✓ |
| SD | Headache | · | · | ✓ |
| SD | Pyrexia | · | · | ✓ |
| SRO | Diarrhoea | ✓ | ✓ | ✓ |
| SRO | Dizziness | ✓ | ✓ | ✓ |
| SRO | Eye pain | ✓ | ✓ | ✓ |
| SRO | Nausea | ✓ | ✓ | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release